Menlo Park, Calif.-Based Foundation Receives Key Funding to Support Goal to Cure Genetic Form of Epilepsy in Children

Today, TESS Research Foundation (TESS) was announced as an awardee of the Chan Zuckerberg Initiative (CZI) Rare As One Project. TESS was selected due to its innovative, patient-led approach to finding a cure and treatments for SLC13A5 Deficiency, a rare genetic epilepsy that causes a lifetime of debilitating seizures that begin within hours of birth. TESS Research Foundation was one of only 30 patient-led organizations in the country to be selected and was awarded $450,000 in grant funding.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200203005601/en/

Maggie (10), Tessa (16, has SLC13A5 Deficiency), Zach (Dad, Founder), Kim (Mom, Founder), Colton (6, has SLC13A5 Deficiency) and Lily (12) (Photo: Business Wire)

As CZI states in their announcement: "Rare disease is anything but rare: as many as 7,000 rare diseases affect 400 million people worldwide. The vast majority of these diseases are not well known or understood, and fewer than five percent have any FDA-approved therapy. The knowledge and learnings of patients suffering from these diseases are key to driving breakthroughs in research and treatment, but a lack of funding and infrastructure to support such patient-led research is holding that progress back."

TESS Research Foundation knows this story all too well. TESS was founded by Kim and Zach Nye, parents of four young children who live in Menlo Park, California. Two of their children, Tessa (age 16) and Colton (age 6), suffer from a rare genetic disorder that was previously unknown and caused the children to have hundreds of seizures daily since birth. The Nyes launched TESS Research Foundation in 2015 to fund research to better understand why mutations in the SLC13A5 gene cause neurological disease and to find the best treatment options. Thanks to the research and collaborations spearheaded by TESS, treatments for the disorder are ready to move into clinical trials within the next two years with sufficient funding. Children around the world have been diagnosed with this disease, which causes chronic seizures, a movement disorder and a severe communication disorder.

"We are so grateful to CZI for their vision and leadership, helping organizations like ours develop cures for diseases like SLC13A5 Deficiency," said Kim Nye, Co-Founder and Executive Director of TESS Research Foundation. "As the mother of two children with SLC13A5 Deficiency, I have watched my children suffer from hundreds of thousands of seizuressomething I hope fewer moms will be able to say in the near future as we discover new cures for genetic epilepsy."

CZI announced $13.5 million in funding to 30 patient-led organizations that are working to find treatments and cures for rare disease. These grants are part of CZIs Rare As One Project, aimed at supporting and lifting up the work that patient communities are doing to accelerate research and drive progress in the fight against rare diseases.

"No one is more committed to finding cures for rare diseases than the patients and families of those affected by these disorders," said Priscilla Chan, Co-Founder & Co-CEO of CZI. "We are proud to support patient-led organizations as they pursue diagnoses, information, and treatment options in partnership with researchers and clinicians."

Story continues

The grant funding will allow TESS to build the infrastructure necessary to raise funding for collaborative research and a cure. The grant will also bring together key stakeholders patients, clinicians, researchers, and industry at the International SLC13A5 Deficiency Research Roundtable March 22-23, 2020 in Dallas, Texas. The TESS Board of Directors and Scientific Advisory Board will remain all-volunteer. Its members include Brenda Porter, MD, PhD, Professor of Neurology and Matthew Bainbridge, PhD, Associate Director of Clinical Genomics Research at Rady Childrens Hospital San Diego, who will also serve as the Primary Clinician and Primary Researcher, respectively, on the TESS Rare As One grant.

"As a pediatric neurologist for the past 23 years, I have taken care of many children with severe neurologic disorders, and the quest for a cure seemed like an unrealistic vision," said Brenda Porter, MD, PhD, Professor of Neurology and head of the TESS Research Foundation Scientific Advisory Board. "Today, I am excited as the path forward for curing genetic disorders including SLC13A5 may be attainable with tools under development. Watching Tessa and Colton, who understand so much but are stuck in bodies they cannot control, is heartbreaking and I look forward to them being able to share who they are with all of us."

For more information about TESS Research Foundation and for complete bios on the Scientific Advisory Board, visit http://www.TESSresearch.org.

For more information about Rare As One, click here.

For more information about the Chan Zuckerberg Initiative, click here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005601/en/

Contacts

Lilly Iffert Singer Associates (415) 227-9700 Lillian@singersf.com

Read the original here:
TESS Research Foundation Selected as Part of Chan Zuckerberg Initiative Rare As One Project - Yahoo Finance